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Abstract
Purpose This review aimed to evaluate the efficacy of intra-articular injections of bone marrow derived mesenchymal stem 
cells (BM-MSCs) for the treatment of knee osteoarthritis (KOA).
Methods This narrative review evaluates recent English language clinical data and published research articles between 
2014 and 2019. Key word search strings of (((“bone marrow-derived mesenchymal stem cell” OR “bone marrow mesen-
chymal stromal cell” OR “bone marrow stromal cell”)) AND (“osteoarthritis” OR “knee osteoarthritis”)) AND (“human” 
OR “clinical”))) AND “intra-articular injection” were used to identify relevant articles using PMC, Cochrane Library, Web 
Of Science and Scopus databases.
Results Pre-clinical studies have demonstrated successful, safe and encouraging results for articular cartilage repair and 
regeneration. This is concluded to be due to the multilineage differential potential, immunosuppressive and self-renewal 
capabilities of BM-MSCs, which have shown to augment pain and improve functional outcomes. Subsequently, clinical 
applications of intra-articular injections of BM-MSCs are steadily increasing, with most studies demonstrating a decrease 
in poor cartilage index, improvements in pain, function and Quality of Life (QoL); with moderate-to-high level evidence 
regarding safety for therapeutic administration. However, low confidence in clinical efficacy remains due to a plethora of 
heterogenous methodologies utilised, resulting in challenging study comparisons. A moderate number of cells (40 × 106) were 
identified as most likely to achieve optimal responses in individuals with grade ≥ 2 KOA. Likewise, significant improvements 
were reported when using lower (24 × 106) and higher (100 × 106) cell numbers, although adverse effects including persistent 
pain and swelling were a consequence.
Conclusion Overall, the benefits of intra-articular injections of BM-MSCs were deemed to outweigh the adverse effects; thus, 
this treatment be considered as a future therapy strategy. To realise this, long-term large-scale randomised clinical trials are 
required to enable improved interpretations, to determine the validity of efficacy in future studies.
Level of evidence IV.




QoL  Quality of life
BM-MSCs  Bone marrow derived-mesenchymal stem 
cells
KOA  Knee osteoarthritis
WHO  World Health Organisation
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BMP2  Bone morphogenetic protein 2
IGF1  Insulin-like growth factor 1
IL-1  Interleukin-1
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WOMAC  The Western Ontario and McMaster Univer-
sities Osteoarthritis Index
VAS  Visual analogue scale
KOOS  Knee injury and osteoarthritis outcome score
MRI  Magnetic resonance imaging
PBS  Phosphate-buffered saline
RCT  Randomised control trial
Introduction
Osteoarthritis (OA) is one of the most ubiquitous joint disor-
ders [1]; the prevalence of symptomatic hip and/or knee OA 
is ~ 242 million worldwide [2] with conditions ranked as the 
11th highest contributors to global disability [1]. Decreased 
patient quality of life (QoL) and productivity poses a sig-
nificant individual and societal burden, with a global preva-
lence of 3.8% [3, 4]. Knee OA (KOA) demonstrates higher 
incidences compared to other joints, with a lifetime risk 
of ~ 45%, increasing to 60.5% amongst obese patients [5]. 
Prevalence increases with each decade of life, with annual 
incidences highest between the ages of 55–65 years [6–9] 
further exacerbated by endogenous and exogenous risk fac-
tors (Table 1).
OA results from degradation of the osteochondral unit 
composed of: articular cartilage; calcified cartilage; sub-
chondral and trabecular bone, which synergistically sup-
port functional loading [10]. Throughout OA progres-
sion, degradative enzymes are overexpressed, including 
matrix metalloproteinases (MMPs) [11], which degrade 
both matrix and non-matrix proteins. Chondrocyte senes-
cence and reduced cartilage elasticity [12] alters the tissue 
microenvironment impairing regeneration. Morphological 
changes in the subchondral bone include cartilage surface 
fibrillation and synovial fluid thickening [13, 14], accom-
panied by progressive synovitis and osteophyte formation. 
Progression according to imaging can be graded as local-
ised (focal) or diffuse (affecting ≥ 75% of the region), and 
normal, doubtful, mild, moderate or severe (grade 0–4 on 
the Kellegren Lawrence scale) [15].
Currently, no conventional or pharmacological thera-
pies have demonstrated unequivocal efficacy in halting dis-
ease progression and injections of molecular compounds 
to assist healing, such as corticosteroids, may only have 
placebic pain reducing effects [16–18]. Surgical interven-
tions may be beneficial when mechanical deformity is pre-
sent; however, therapeutic benefit is limited to late-stage 
OA and is not considered as a long-term solution. Alter-
natively, cellular regenerative therapies, including mesen-
chymal stem cells (MSCs) [19] and cell-derived products 
(such as platelet-rich plasma [20]) have shown therapeutic 
promise. Since OA is degenerative, likely involving endog-
enous MSC depletion, investigation into this therapy is 
supported by BM-MSCs inherent characteristics (Fig. 1) 
and their potential for articular cartilage repair/regenera-
tion [21].
The purpose of this study was to review published 
literature to assess and evaluate the clinical efficacy of 
intra-articular injections of bone marrow-derived MSCs 
(BM-MSCs) specifically for KOA. It was hypothesized 
that BM-MSCs would have a beneficial impact on KOA 
clinical outcomes. This is clinically relevant since OA 
poses a significant individual, societal and economic 
global burden.
Table 1  Endogenous and exogenous risk factors for KOA
Adapted from: Adatia et al. [64] and supplemented by Palmer [65]
Endogenous Exogenous
Age Previous joint injuries
 Incidence rates increase linearly in the 50–80 age range
Sex Body mass
 Females have been reported to have a greater incidence rate 
compared to males
Overweight and obese people are significantly associated with higher KOA risk
The risk increases by 35% with every 5 kg/m2 increase in BMI
Heredity Excessive joint stress and increased mechanical forces
Genetics Repetitive loading (kneeling and squatting)
Joint laxity Occupation
Physical work activities (kneeling/squatting/lifting and climbing) contribute to 
the occurrence/progression of KOA
Ethnic origin Resective joint surgery
 More common in individuals of European descent
 Post-menopausal changes Muscle weakness
 Malalignment Lifestyle factors (alcohol, tobacco use)
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Methods
A systematic literature search was performed using elec-
tronic databases PMC (PubMed), Cochrane Library, Web 
of Science and Scopus, to identify recent English language 
clinical data published between 2014 and 2019. Keyword 
search strings of (((“bone marrow-derived mesenchymal 
stem cell” OR “bone marrow mesenchymal stromal cell” 
OR “bone marrow stromal cell”)) AND (“osteoarthritis” 
OR “knee osteoarthritis”)) AND (“human” OR “clinical”))) 
AND “intra-articular injection” were applied. Cell dosages 
were analysed and compared. Despite results being predomi-
nantly positive, to increase confidence in clinical efficacy 
and comparability there needs to be a standardisation of 
methodologies including follow-up durations and appro-
priate controls and the application of quantitative outcome 
measures.
Results
Using the search terms described returned 139 records; 117 
from PMS, 6 from Cochrane Library, 7 from Web of Sci-
ence and 14 from Scopus respectively. A further five records 
were identified via other searches. The removal of duplicate 
records resulted in 133 records being screened for relevance 
(Fig. 2). The titles and abstracts were screened, and 100 
records were removed since they were unrelated, in vitro 
studies, non-human studies and/or review articles. Of the 
23 full-text articles assessed for eligibility, 9 records were 
excluded due to the methods employing combined treat-
ments, i.e. BM-MSCs administered with chondrocytes or 
hyaluronic acid, the cells not being bone-marrow derived 
or the studies being non-knee specific. 14 studies were 
included in a qualitative synthesis. Due to the low number 
of published studies, coupled with the diversity of protocols 
implemented and significant variation in outcome measures 
applied it was extremely difficult to directly quantitatively 
compare studies. Thus, a narrative review was felt to be most 
appropriate to review and present the relevant literature.
Discussion
BM‑MSCs for stimulating regeneration in knee 
osteoarthritis
Bone marrow tissue supports the complex microenvironment 
for numerous cell types and bone marrow aspirate can be 
used whole, concentrated, or as a source for stem cells [19]. 
BM-MSCs can be isolated from aspirate and have gained 
significant attention in the regenerative medicine field [22] 
Fig. 1  The function of MSCs play a significant role in the repair and 
regeneration process and are identified in this diagram. These include 
the reduction of cell death to continually replace lost cells, the secre-
tion of trophic factors which stabilise the extracellular matrix and 
the suppression of immune cell activation to prevent inflammation. 
Adapted from: BioExplorer.net [63]
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due to their multilineage differentiation potential, immu-
nomodulatory and self-renewal capacities [21, 23].
BM-MSCs promote repair via paracrine signalling mech-
anisms and the secretion of soluble trophic factors includ-
ing bone morphogenetic protein-2 (BMP2) and insulin-like 
growth factor-1 (IGF1) [24]. These factors enhance cellular 
regeneration and induce bone formation by stimulating pro-
liferation and differentiation of endogenous semi-like pro-
genitors found in most tissues and by decreasing OA inflam-
matory and immune reactions [25]. BM-MSCs also inhibit 
T- and B-lymphocyte activation by inhibiting inflammatory 
cytokine production, thereby preventing immune responses 
and consequently promoting immune tolerance. Further-
more, BM-MSCs stimulate anti-inflammatory interleu-
kin-1 (IL-1) supporting the generation of anti-inflammatory 
T-cells [26]. To guarantee these characteristics and stand-
ardise MSC classification, the Mesenchymal and Tissue 
Stem Cell Committee of the International Society for Cel-
lular Therapy (ISCT) has defined MSC criteria (Table 2) to 
improve the validity and consistency of research trials.
Pre-clinical studies investigating BM-MSCs for carti-
lage repair in animal models have demonstrated encour-
aging results (Table 3) [27–33]; subsequently, clinical 
applications are increasing (Table 4) [30, 34–44]. BM-
MSCs administered for KOA in clinical patients adhere to 
damaged tissue surfaces, and differentiate into chondro-
cytes, resulting in anatomic restoration with significant 
improvements regarding pain and function [40, 43]. How-
ever, some studies have challenged whether BM-MSCs 
treatments are applicable to all OA grades [45–47]. Across 
Fig. 2  PRISMA flowchart of 
study selection criteria
Table 2  Committee of the ISCT 
criteria for the classification of 
mesenchymal stem cells [66]
Classification of MSCs
Fibroblastic-like (spindle-shaped) morphology
Plastic-adherent property under standard culture conditions
Differentiation potential into osteoblasts, adipocytes, and chondroblasts in vitro
Expression of surface markers including CD105; CD73 and; CD90
Lack of expression of: CD45; CD34; CD14; or CD11b; CD79α or CD19 and; HLA-DR
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research studies, a variety of outcome measures have been 
utilised, with some studies reliant upon qualitative ques-
tionnaires including The Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) and Lequesne 
algofunctional indexes [20] to evaluate success, which 
may introduce unintended bias [38, 42], due to physicians 
influencing patient responses. This may be improved by 
digital administration of questionnaires therefore, it will be 
completed individually with no external input [48].
Within the literature reviewed, the follow-up periods 
and outcome criteria varied. Periods up to 12-month 
post-injection have been followed, with clinical outcomes 
including increased cartilage thickness, function and pain 
measured [34]. Despite reported improvements, not all 
are significant. Contrastingly, greater BM-MSC longevity 
with significant changes in both qualitative and quantita-
tive after-effects have been reported [34, 44, 49]. An injec-
tion of 40 × 106 cells in 12 patients with advanced KOA 
displayed significant improvements in VAS and quality of 
articular cartilage without diminution between a 12 [40] 
and 24-month follow-up [44]. Davatchi et al. [37] reported 
a 5-year follow-up post injection of 8–9 × 106 BM-MSCs 
in 4 patients and observed progressive deterioration, 
although outcomes were improved compared to baseline 
measurements, suggesting a protective role of BM-MSCs 
compared to untreated controls. Despite prolonged follow-
up periods, limited patient numbers and lack of in-depth 
statistical analysis make it difficult to draw robust conclu-
sions regarding the overall therapeutic efficacy [50].
Compared to autologous BM-MSCs, allogenic BM-
MSCs represent an alternative cell source. Multiple ran-
domised control trials (RCTs) have reported improved out-
comes with various doses (25 × 106–50 × 106 cells), which 
are safe and well tolerated, whereas higher doses can pro-
duce adverse events [30]. Despite positive trends in similar 
studies [43, 44], few clinical parameters were significantly 
improved; with no critical changes in X-ray and Magnetic 
Resonance Imaging (MRI) compared to baseline measure-
ments. Although BM-MSCs are considered poorly immu-
nogenic, allogenic cells may stimulate immune responses 
and thus, the identification of an optimum dose is crucial 
for viable treatment strategies [50].
There is currently limited evidence for simultaneous 
improved clinical outcomes, including pain, function, 
and cartilage repair. However, improvements following 
the application of intra-articular BM-MSCs at short-term 
follow-up have been reported [22]. Several studies have 
reported improved cartilage thickness; however, meaning-
ful changes in clinical outcomes are sporadic. Moreover, 
studies using both autologous and allogenic BM-MSCs 
have been explored within the literature, including co-
administered and ex-vivo expanded treatments [30, 49].
Critique of BM‑MSC intra‑articular injections 
for the treatment of knee osteoarthritis
Autologous BM-MSC injections are the dominant cell 
choice in clinical studies reported for treating KOA [51]. 
In an early case report [35], a single patient was injected 
with 22.4 × 106 cells suspended in phosphate-buffered saline 
(PBS) with a dexamethasone post-injection as a differentiat-
ing agent [52]. The 3-month follow-up reported no adverse 
events, with significantly increased cartilage and menis-
cus growth, with minor improvements in range of motion 
(ROM) and pain scores. This was the first report of increased 
meniscus size in humans; however, the methodology lacked 
specificity and a detailed exploration of the dexamethasone 
effects was not conveyed [52]. MRI revealed significant 
cartilage thickening covering the distal femur and proxi-
mal tibia at 6 and 12 months, yet symptomatic and func-
tional improvements were not apparent. This study failed to 
acknowledge potential author or methodological bias and 
so further pilot and clinical studies are required to replicate 
meaningful findings.
Davatchi et al. [36] emphasised the safety of BM-MSC 
injections, claiming marked improvements in (qualitative) 
outcome parameters, with physical parameters improving to 
a lesser extent. In comparison to Centeno et al. [35], a lower 
dosage of 8–9 × 106 BM-MSCs were administered, poten-
tially accounting for lower physical parameter improve-
ments. The follow-up from a 2011 case series [37] argued 
that the lack of significant outcomes is due to all participants 
having advanced-stage OA.
Emadedin et al. [38] performed a similar study on a small 
patient cohort (n = 6), using 20–24 × 106 cells, reporting sig-
nificant improvements in pain and function (WOMAC) at 
both 6 and 12 months. A long-term follow-up of the same 
cohort affirmed previous findings, revealing that BM-MSC 
dosages were safe and therapeutically beneficial. Neverthe-
less, between 12 and 30 months, therapeutic improvements 
declined in all individuals, suggesting the need for subse-
quent administration for prolonged benefit [39].
Despite reported therapeutic benefits of BM-MSCs, the 
generalisability of the results and techniques used for larger 
populations with symptomatic KOA is limited. This high-
lights the requirement for larger, blinded RCTs to improve 
study comparability and clinical validity. Likewise, within 
study designs, sample size calculations should be utilised 
for methodological and ethical reasons. Otherwise, reported 
findings should be interpreted with caution, as smaller sam-
ples may undermine internal and external study validity.
A clinical RCT (phase I/II) of 30 patients with grade 
≥ 2 OA used a sample size calculation that provided 
an effect size of 0.6 and, a power of 80% [49]. Group 
randomisation was performed, potentially facilitating 
the increased cohort size compared to previous studies 
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(n = 30), whilst reducing bias [53]. Despite randomisa-
tion, the stage of OA was more severe in those receiv-
ing low-dose BM-MSCs (10 × 106), which may have pre-
vented these patients achieving more positive outcomes 
[49]. The study included blinded radiologists to reduce 
bias (extra KOA MRIs were randomly added during 
analysis). Ethical issues prevented double-blinding; thus, 
qualitative clinical scores were compared with objective 
measures to minimise bias. A control, low-dose and high-
dose group were followed for 12 months. Outcomes were 
significant at 3, 6 and 12 months and correlations revealed 
a significant reduction in low-and-high-dose VAS scores 
at all time points, which correlated with improved ROM 
compared to the control group. Importantly, this study 
co-administered hyaluronic acid (HA) and indicated that a 
single injection is a safe and feasible procedure, resulting 
in both clinical and functional improvements; particularly 
when 100 × 106 cells were administered.
Additional studies using allogenic BM-MSCs also used 
HA either as a control group or as a cell suspension [43, 
44]. However, cells from young, healthy donors may not 
reflect growth and differentiation characteristics of MSCs 
from elderly and/or OA patients [54]. Yet, they equally 
showed improvements in pain and function. Espinosa 
et al. [55] described a decrease in knee joint space in 
control groups (HA) at 12 months. Whereas Vangsness 
et al. and Vega et al. [43, 44] provided MRI analysis using 
T2 mapping of cartilage and, computational analysis of 
meniscus volume to assess the effects of BM-MSCs more 
closely. Vega et al. [44] found significant decreases in 
poor cartilage index (PCI) at 12-month following injec-
tion of 40 × 106 cells. Conversely, a dosage of 50 × 106 
cells [43] identified significantly increased meniscus 
volume (> 15%) at 12 months, which continued 2 years 
post-injection. Orozco et al. [40] also reported significant 
improvements in PCI following treatment with autologous 
BM-MSCs with continued improvement over the 2-year 
follow-up. A significant correlation between VAS and 
PCI was reported, demonstrating that both cartilage and 
pain/function improvements occur simultaneously. This 
study supersedes previous case reports where results were 
described as “satisfactory” [39], as cell dosages were 
larger, the follow-up was longer and the MRI investiga-
tion provided robust quantitative analysis.
Alternative methodologies for the application of MSCs 
into KOA patients exist, however these are more invasive 
but do allow more specific targeting of focal cartilage 
defects. Brittberg et al. and Bornes et al. have both com-
prehensively discussed the use of MSCs (not just lim-
ited to BM-MSCs) in the specific treatment of cartilage 
defects considering multiple therapy options [56, 57].
Safety considerations when using BM‑MSCs 
for the treatment of KOA
The feasibility and safety of both allogenic and autolo-
gous cells have been reiterated throughout literature [40, 
41]; yet, studies utilising higher doses regularly report 
increased adverse events. In a sample of 55 patients, 247 
adverse events were reported, with one life-threatening, 
1-year post-injection when using allogenic BM-MSCs [43]. 
Minor adverse events, such as post-implantation pain and 
inflammation, occur with similar frequencies (50%) between 
studies using autologous BM-MSCs [40, 49]. Most adverse 
events were resolved within 24–48 h following treatment 
with pain medication. Nevertheless, adverse events were not 
reported in every study [35, 39, 41].
Close attention to adverse events may be key to clini-
cal translation when optimising BM-MSCs as a KOA ther-
apy [51]. The majority of literature reports use of either 
autologous or allogenic BM-MSCs, however studies have 
also included infused BM-MSCS [30, 42]. Soler et al. [42] 
produced an analysis of a prospective, open-label, single-
arm clinical trial for the infusion of XCEL-M-Alpha into 
autologous BM-MSCs. Significant improvements in VAS, 
WOMAC and Lequesne algofunctional index were observed 
following a 40 × 106 injection. However, this is one of the 
first to infuse BM-MSCs and the omission of control groups 
makes it difficult to evaluate efficacy. The indistinct method 
regarding infusion is inconsistent with the detailed explana-
tion of cell isolation and expansion and therefore, the meth-
odology may be lacking suitable description. Furthermore, 
Gupta et al. [30] injected ex vivo expanded, pooled allogenic 
BM-MSCs  (Stempeucel®) into 60 patients who were split 
into four different dosage groups (with a control each) in a 
randomised, double-blinded multicentre placebo-controlled 
study (RCT). However, unblinding of the trial occurred after 
6-month follow-up even though subjective measurements 
were continuously analysed; after this point, results should 
be interpreted with circumspection. The therapeutic effect of 
BM-MSCs was not explored without HA, but both pre-clini-
cal and clinical studies suggest that BM-MSCs co-adminis-
tered with HA tends to produce greater regenerative benefit 
[58]. This study also failed to produce any significant out-
comes, which was potentially due to the procedure employed 
with higher dosages and volumes (75 and 150 million cells) 
being restricted in the limited joint space; possibly causing 
cell aggregation. The study may have been more valuable if 
lower dosages were also examined.
Overall, there is moderate-to-high level evidence of 
safety to recommend therapeutic administration of BM-
MSCs for KOA, for both animal and human studies; sug-
gesting therapeutic benefit. Several published results, 
especially conclusions and speculations drawn from case/
preliminary reports, do not have the weight of findings 
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compared to RCTs. Therefore, when interpreting results, 
due diligence is recommended. Furthermore, the signifi-
cance of experimental outcomes may be influenced by the 
prevalent study heterogeneity including: the use of a vari-
ety of cell doses and donors; variability in functionality 
and pain scores; severity of KOA; various cell processing 
methods and differing follow-up periods [59].
Due to the immune-privileged status of MSCs [60], 
allogenic BM-MSCs show more promise compared to 
autologous, since they allow manufacturing of large 
batches or ‘off-the-shelf’ products in the future [61]. This 
would enhance the reliability of production whilst decreas-
ing the costs of cell therapies [62], however, long-term 
efficacy data are warranted.
Conflicting study results may result from methodologi-
cal heterogeneity or, the limitation of BM-MSCs remain-
ing localised within the tissue. This may be caused by the 
rapid cycling of synovial fluid or due to large volumes 
injected into the knee causing cell apoptosis. Despite 
reported adverse events, the outcomes across the published 
studies are influential in demonstrating that the benefits 
may outweigh the treatment risks. Despite BM-MSCs 
intra-articular injections potentially having a limited 
therapeutic effect on cartilage volume [51], the clinical 
and functional outcomes are favourable in patients with 
chronic KOA. In terms of evaluating BM-MSC efficacy, 
it may be more applicable for future studies to only focus 
on long-term, large-scale RCTs as non-RCTs tend to have 
greater bias and more confounders, affecting the interpre-
tation and validity of efficacy [22]. Future studies need to 
determine the type and quality of the repaired cartilage 
tissues, its durability and the association between objective 
and subjective outcome improvements [22].
Conclusion
It is apparent that moderate-high cell numbers (40 × 106) 
are most likely to achieve optimal responses in individu-
als with grade ≥ 2 KOA. The highest number of cells used 
(100 × 106) also produced significant improvements in 
KOA, although this came at a cost, with greater risks of 
adverse events. Therefore, the number and type of cell 
donor BM-MSCs, the timing of injection, the stage of 
the disease and the number of injections requires further 
investigation to achieve optimal therapeutic benefit.
Subsequently, a unified classification of intra-articular 
dosage and efficacy needs to be agreed before safe and 
effective treatment can be implemented as a leading regen-
erative treatment strategy, across all OA populations.
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